Logo Image
News
All NewsBlogs
Media
All VideosCase-Based Roundtable SeriesEichenbaum AcornsExpert InterviewsEyeviewsInsightsMedical World NewsPodcastsRapid ReadoutsThe Retina TL;DRThe Wills Retina ReportViewpoints
Conferences
Conference CoverageConference Listing
Publications
Modern Retina Digital EditionSupplements And Featured Publications
More
Resources
Between the LinesCME/CEEYLEA 8mg for nAMD and DME TreatmentSponsored Resources
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Resources
  • Partners
  • Subscribe
  • AMD
    • Wet AMD
  • Biosimilar
  • Diabetic Macular Edema
    • Diabetic Eye Awareness
  • Diabetic Retinopathy
  • Geographic Atrophy
  • Imaging
  • Inherited Retinal Diseases
  • RVO
  • Retina Technology
  • Retinal Surgery
  • Uveitis
Spotlight -
Geographic Atrophy
Advertisement

Ramin Tadayoni, MD, PhD

Advertisement

Articles by Ramin Tadayoni, MD, PhD

EURETINA 2021: Pre-conference interview with Dr. Ramin Tadayoni

Discussing worldwide pathological myopia

ByCaroline Richards,Ramin Tadayoni, MD, PhD
September 11th 2021

Dr. Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.

The posterior segment: In search of topical treatment options

The posterior segment: In search of topical treatment options

ByRamin Tadayoni, MD, PhD
May 21st 2021

Novel therapies are shifting the paradigm in care of retinal diseases

Advertisement

Latest Updated Articles

  • The posterior segment: In search of topical treatment options
    The posterior segment: In search of topical treatment options

    May 21st 2021

  • EURETINA 2021: Pre-conference interview with Dr. Ramin Tadayoni
    Discussing worldwide pathological myopia

    September 11th 2021



Advertisement
Advertisement

Trending on Modern Retina

1

Revakinagene taroretcel-lwey for MacTel: Charles Wykoff, MD, PhD, on a year of real-world experience

2

Vaccinated patients show markedly lower risk of new-onset idiopathic uveitis

3

Optimizing anti-VEGF in AMD, DME, and RVO: Strategies for durable disease control

4

Phase 3 data support OTX-TKI’s durability in wet AMD: 1 injection, 1 year

5

Detecting peripheral retinal lesions in children with myopia

  • About
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us